Free tool
FAERS Monitor: Ilevro
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 203491 or its brand name (Ilevro, Nepafenac). Reports on generic versions are filed under their own applications.
Reports
1,718
Serious
588
34% of reports
Hospitalization
168
Death reported
39
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- eye pain376
- drug ineffective119
- vision blurred110
- off label use65
- eye irritation64
- product quality issue58
- visual impairment55
- liquid product physical issue53
- cataract52
- fatigue48
- chronic kidney disease41
- incorrect dose administered41
- cystoid macular oedema35
- diarrhoea34
- product container issue31
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2008 | 17 |
| 2010 | 2 |
| 2012 | 4 |
| 2013 | 11 |
| 2014 | 24 |
| 2015 | 70 |
| 2016 | 232 |
| 2017 | 577 |
| 2018 | 158 |
| 2019 | 188 |
| 2020 | 143 |
| 2021 | 80 |
| 2022 | 43 |
| 2023 | 54 |
| 2024 | 56 |
| 2025 | 39 |
| 2026 | 20 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,441 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| cystoid macular oedemaSignal | 35 | 231.7 | 166.4 | 7,667 |
| liquid product physical issueSignal | 53 | 89.6 | 68.7 | 4,524 |
| eye painSignal | 376 | 82.1 | 75.1 | 29,932 |
| product container issueSignal | 31 | 44.4 | 31.3 | 1,269 |
| eye irritationSignal | 64 | 13.6 | 10.7 | 737 |
| cataractSignal | 52 | 10.7 | 8.2 | 448 |
| vision blurredSignal | 110 | 9.8 | 8.2 | 867 |
| chronic kidney diseaseSignal | 41 | 6.6 | 4.9 | 190 |
| visual impairmentSignal | 55 | 5.4 | 4.2 | 196 |
| product quality issueSignal | 58 | 5.2 | 4.1 | 195 |
| incorrect dose administeredSignal | 41 | 2.2 | 1.6 | 26 |
| drug ineffective | 119 | 1.1 | 0.9 | 1 |
| off label use | 65 | 0.9 | 0.7 | 1 |
| fatigue | 48 | 0.8 | 0.6 | 4 |
| diarrhoea | 34 | 0.6 | 0.5 | 7 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.